Answers are grounded in this paper and cite their sources.
Background: A putative link between thyroid dysfunction and the natural history of breast cancer is controversial, but numerous studies suggest that primary hypothyroidism is associated with a biologically less aggressive and clinically more indolent disease.Hence, in cancer patients with primary hypothyroidism, modification of the daily dose of L-thyroxine might potentially affect the course and prognosis of active breast cancer.Methods: 2,044 charts were reviewed in a hospital-based retrospective case-control study of 159 female patients with AJCC stage 1-4 invasive breast cancer over a 10-year period.68 cases of invasive breast cancer with primary hypothyroidism were compared to 91 matched controls.The differences in age of diagnosis, survival and clinic opathological variables were analyzed for the two groups.Results: Compared to euthyroid patients those with hypothyroidism were diagnosed with breast cancer 4.7years later (mean age at diagnosis 68.12 vs. 63.44 years, p <0.035).The primary tumor measured <1 cm in 27.4% of hypothyroid vs. 11.4% of euthyroid patients, p <0.047.Hypothyroid patients were less likely to have lymph node involvement (21.6 vs. 40.5,p <0.28) and more likely to have low S phase fraction (79.4 vs. 60.4,p <0.21).There was insufficient data for thyroid function correlation and survival analysis.Conclusion: Therefore, in women with L-thyroxine supplemented primary hypothyroidism, breast cancer is diagnosed over a 4 subclinical years later age than in a euthyroid cohort and is a less aggressive disease.Prospective clinical and thyroid function correlative studies are indicated to validate these findings.
No takes yet. Share an insight, caveat, or question.
Saira Khalid (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: